Literature DB >> 21813138

Sleep disturbances in multiple sclerosis.

Ana Caminero1, Manuel Bartolomé.   

Abstract

OBJECTIVES: The frequency of sleep disturbances in multiple sclerosis (MS), and their impact on the quality of life of MS patients, have traditionally been underestimated. Here we review the most common sleep disorders seen in this disease, their prevalence, pathophysiology, clinical manifestations and current treatments.
METHOD: We begin with a brief description of epidemiological data on sleep disturbances in MS, explain how these disturbances increase potential associated morbidities, and discuss the bidirectional relationship established between these two comorbid conditions (i.e. MS worsens sleep disturbances and vice versa). We then analyze the main dyssomnias and parasomnias described in MS: insomnia, circadian rhythm disorders, drug-induced sleep disturbances, restless legs syndrome (RLS) and periodic leg movements (PLM), respiratory disorders during sleep, narcolepsy-cataplexy syndrome and REM sleep behavior disorder (RBD). We also review the relationship between sleep disturbances and chronic fatigue syndrome, which is very frequent in MS patients.
CONCLUSION: Sleep disturbances are more common in MS patients than in the general population and limit these patients' quality of life. Therefore, we believe that these disturbances should be a focal point in any multidisciplinary treatment for MS.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21813138     DOI: 10.1016/j.jns.2011.07.015

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  26 in total

1.  Sleep and oligodendrocyte functions.

Authors:  Michele Bellesi
Journal:  Curr Sleep Med Rep       Date:  2015-03-01

2.  Case Report: Rapid Eye Movement Sleep Behavior Disorder as the First Manifestation of Multiple Sclerosis: A Case Report and Literature Review.

Authors:  Alejandro Enriquez-Marulanda; Valentina Quintana-Peña; Yuri Takeuchi; Jairo Quiñones
Journal:  Int J MS Care       Date:  2018 Jul-Aug

Review 3.  Sleep and neurological autoimmune diseases.

Authors:  Alex Iranzo
Journal:  Neuropsychopharmacology       Date:  2019-07-14       Impact factor: 7.853

Review 4.  Potential Circadian Rhythms in Oligodendrocytes? Working Together Through Time.

Authors:  Christopher S Colwell; Cristina A Ghiani
Journal:  Neurochem Res       Date:  2019-03-25       Impact factor: 3.996

5.  Low Prevalence of Sleep Disorders in Demyelinating Disease in a Northern Tenerife Population.

Authors:  Montserrat González-Platas; Javier González-Platas; Moises Bermúdez-Hernández; Maria Yaiza Pérez-Martín; Cristina Croissier-Elías; Pedro Javier Pérez-Lorensu
Journal:  J Clin Sleep Med       Date:  2016-06-15       Impact factor: 4.062

6.  Restless legs syndrome in Iranian patients with multiple sclerosis.

Authors:  Shahnaz Miri; Mohammad Rohani; Mohammad Ali Sahraian; Babak Zamani; Gholam Ali Shahidi; Amin Sabet; Maziar Moradi-Lakeh; Mohammad Bodaghabadi
Journal:  Neurol Sci       Date:  2012-09-09       Impact factor: 3.307

7.  Sleep Disturbance and Cognitive Dysfunction in Multiple Sclerosis: a Systematic Review.

Authors:  Abbey J Hughes; Katherine M Dunn; Trisha Chaffee
Journal:  Curr Neurol Neurosci Rep       Date:  2018-01-29       Impact factor: 5.081

8.  Poor sleep quality in patients with multiple sclerosis: gender differences.

Authors:  Marianna Vitkova; Jaroslav Rosenberger; Zuzana Gdovinova; Jarmila Szilasiova; Pavol Mikula; Johan W Groothoff; Sijmen A Reijneveld; Jitse P van Dijk
Journal:  Brain Behav       Date:  2016-09-20       Impact factor: 2.708

9.  Sleep disturbances in patients with multiple sclerosis.

Authors:  Anna Pokryszko-Dragan; Małgorzata Bilińska; Ewa Gruszka; Łukasz Biel; Katarzyna Kamińska; Katarzyna Konieczna
Journal:  Neurol Sci       Date:  2012-10-30       Impact factor: 3.307

10.  Melatonin acts as antioxidant and improves sleep in MS patients.

Authors:  Monika Adamczyk-Sowa; Krystyna Pierzchala; Pawel Sowa; Sebastian Mucha; Izabela Sadowska-Bartosz; Jowita Adamczyk; Marcin Hartel
Journal:  Neurochem Res       Date:  2014-06-30       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.